Acadian Asset Management LLC Verastem, Inc. Transaction History

Acadian Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.39 - $0.71 $79,139 - $144,075	-202,923 Reduced 7.56%	2,479,786 $1.03 Million
Q4 2022 Feb 14, 2023	BUY	$0.33 - $10.44 $769,851 - $24.4 Million	2,332,884 Added 666.87%	2,682,709 $1.08 Million
Q3 2022 Nov 14, 2022	SELL	$0.92 - $11.16 $60,130 - $729,406	-65,359 Reduced 15.74%	349,825 $297,000
Q2 2022 Aug 09, 2022	SELL	$1.02 - $1.83 $612,382 - $1.1 Million	-600,375 Reduced 59.12%	415,184 $481,000
Q1 2022 May 12, 2022	SELL	$1.06 - $2.1 $430,210 - $852,303	-405,859 Reduced 28.55%	1,015,559 $1.43 Million
Q4 2021 Feb 10, 2022	SELL	$2.05 - $3.2 $945,781 - $1.48 Million	-461,357 Reduced 24.5%	1,421,418 $2.91 Million
Q3 2021 Nov 12, 2021	BUY	$2.54 - $4.07 $2.08 Million - $3.33 Million	818,991 Added 76.99%	1,882,775 $5.8 Million
Q2 2021 Aug 11, 2021	BUY	$2.57 - $4.85 $2.67 Million - $5.04 Million	1,038,577 Added 4120.19%	1,063,784 $4.33 Million
Q1 2021 May 11, 2021	BUY	$1.9 - $2.82 $47,893 - $71,083	25,207 New	25,207 $62,000
Q4 2017 Jan 18, 2018	SELL	$2.99 - $4.85 $126,805 - $205,688	-42,410 Closed	0 $0
Q3 2017 Oct 13, 2017	BUY	$3.01 - $5.41 $127,654 - $229,438	42,410	42,410 $199,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $779M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.